Lannett: LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products.
Read full article »
Lannett is a Pennsylvania-based pharmaceutical company that manufactures and commercializes drugs for the treatment of generic diseases.
Read more